Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.43-$3.49 to $3.34-$3.41 vs $3.45 Est; Lowers FY2026 Sales Guidance from $22.181B-$22.383B to $21.479B-$21.780B vs $22.228B Est

Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.43-$3.49 to $3.34-$3.41 vs $3.45 analyst estimate. Lowers FY2026 sales outlook from $22.181 billion-$22.383 billion to $21.479 billion-$21.780 billion vs $22.228 billion estimate.